Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Spectral Medical Inc. (EDT.TO)
Toronto, ON, CA
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +1.45% | +7.69% | +3.70% | -2.78% | +66.67% | +418.52% | +191.67% | +32.08% | -83.53% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+6.8% Q1'26: +55.8% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-210.2% Q1'26: +77.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-695.5% Q1'26: -267.8% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%-478.5% Q1'26: -379.8% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%— Q1'26: +26.8% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+2.2% Q1'26: +3.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-1.84× Q1'26: -1.68× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.67M
est: 2.62M (+2.1%)
|
2.96M
est: 3.04M (-2.7%)
|
3.09M
est: 3.07M (+0.5%)
|
3.55M
est: 3.40M (+4.3%)
|
3.67M
est: 3.70M (-0.8%)
|
3.84M
est: 18.90M (-79.7%)
|
2.87M
est: 2.90M (-1.1%)
|
2.10M
est: 2.10M (+0.0%)
|
2.00M
est: 2.00M (-0.2%)
|
1.67M
est: 1.60M (+4.2%)
|
1.60M
est: 1.70M (-6.0%)
|
2.29M
est: 2.10M (+8.9%)
|
2.44M
est: 2.60M (-6.1%)
|
2.81M
2.59M – 3.03M
+7.9% YoY
|
13.75M
12.51M – 14.99M
+389.8% YoY
|
47.79M
44.05M – 51.52M
+247.6% YoY
|
136.87M
126.17M – 147.57M
+186.4% YoY
|
199.73M
184.12M – 215.35M
+45.9% YoY
|
| EBITDA |
-10.64M
est: -2.62M (-306.5%)
|
-9.40M
est: -12.80M (+26.6%)
|
-8.91M
est: -3.07M (-189.8%)
|
-9.23M
est: -3.40M (-171.5%)
|
-3.17M
est: -11.46M (+72.4%)
|
-2.26M
est: -18.90M (+88.0%)
|
-4.55M
est: -8.41M (+45.9%)
|
-8.76M
est: -3.63M (-141.1%)
|
-6.38M
est: -11.85M (+46.2%)
|
-7.18M
est: -63.67M (+88.7%)
|
-13.96M
est: -274.89M (+94.9%)
|
-11.97M
est: -1.19B (+99.0%)
|
-11.44M
est: -2.60M (-339.6%)
|
-2.81M
-3.03M – -2.59M
-7.9% YoY
|
-13.75M
-14.99M – -12.51M
-389.8% YoY
|
-47.79M
-51.52M – -44.05M
-247.6% YoY
|
-136.87M
-147.57M – -126.17M
-186.4% YoY
|
-199.73M
-215.35M – -184.12M
-45.9% YoY
|
| EBIT |
-10.88M
est: -2.62M (-315.6%)
|
-9.60M
est: -13.22M (+27.4%)
|
-9.08M
est: -3.07M (-195.3%)
|
-9.46M
est: -3.40M (-178.1%)
|
-3.39M
est: -11.88M (+71.5%)
|
-2.49M
est: -18.90M (+86.8%)
|
-4.82M
est: -8.71M (+44.6%)
|
-9.07M
est: -3.85M (-135.2%)
|
-6.67M
est: -12.57M (+46.9%)
|
-7.45M
est: -67.54M (+89.0%)
|
-14.17M
est: -291.57M (+95.1%)
|
-12.22M
est: -1.26B (+99.0%)
|
-11.69M
est: -2.60M (-349.3%)
|
-2.81M
-3.03M – -2.59M
-7.9% YoY
|
-13.75M
-14.99M – -12.51M
-389.8% YoY
|
-47.79M
-51.52M – -44.05M
-247.6% YoY
|
-136.87M
-147.57M – -126.17M
-186.4% YoY
|
-199.73M
-215.35M – -184.12M
-45.9% YoY
|
| Net Income |
-11.31M
est: -22.71M (+50.2%)
|
-9.49M
est: -13.15M (+27.8%)
|
-9.52M
est: -14.05M (+32.2%)
|
-10.15M
est: -10.53M (+3.7%)
|
-4.08M
est: -11.80M (+65.5%)
|
-2.49M
est: -2.81M (+11.4%)
|
-4.86M
est: -8.66M (+43.9%)
|
-9.10M
est: -3.85M (-136.0%)
|
-8.79M
est: -12.57M (+30.1%)
|
-11.28M
est: -67.54M (+83.3%)
|
-15.66M
est: -291.57M (+94.6%)
|
-15.40M
est: -1.26B (+98.8%)
|
-47.69M
est: -38.02M (-25.4%)
|
-9.42M
-10.38M – -8.46M
+75.2% YoY
|
—
— – —
+100.0% YoY
|
20.10M
18.06M – 22.15M
|
57.44M
51.60M – 63.28M
+185.7% YoY
|
94.78M
85.14M – 104.41M
+65.0% YoY
|
| SGA |
11.01M
est: 13.30M (-17.2%)
|
10.04M
est: 15.47M (-35.1%)
|
11.31M
est: 15.61M (-27.6%)
|
10.37M
est: 17.27M (-40.0%)
|
5.36M
est: 18.79M (-71.5%)
|
4.98M
est: 96.00M (-94.8%)
|
5.86M
est: 14.73M (-60.2%)
|
9.57M
est: 10.67M (-10.3%)
|
7.01M
est: 10.16M (-31.0%)
|
8.64M
est: 8.13M (+6.3%)
|
11.29M
est: 8.64M (+30.8%)
|
11.62M
est: 9.13M (+27.2%)
|
2.20M
est: 11.31M (-80.6%)
|
12.21M
11.25M – 13.16M
+7.9% YoY
|
59.79M
54.39M – 65.19M
+389.8% YoY
|
207.80M
191.56M – 224.05M
+247.6% YoY
|
595.17M
548.64M – 641.70M
+186.4% YoY
|
868.51M
800.61M – 936.41M
+45.9% YoY
|
| EPS |
-0.09
est: -0.08 (-9.2%)
|
-0.06
est: -0.08 (+24.0%)
|
-0.05
est: -0.05 (-1.2%)
|
-0.05
est: -0.04 (-24.0%)
|
-0.02
est: -0.03 (+33.3%)
|
-0.01
est: -0.01 (-13.0%)
|
-0.02
est: -0.04 (+46.0%)
|
-0.04
est: -0.04 (+3.5%)
|
-0.03
est: -0.03 (-15.0%)
|
-0.04
est: -0.05 (+16.2%)
|
-0.06
est: -0.04 (-40.5%)
|
-0.05
est: -0.07 (+21.7%)
|
-0.17
est: -0.14 (-21.4%)
|
-0.03
-0.04 – -0.03
+76.6% YoY
|
—
— – —
+100.0% YoY
|
0.07
0.06 – 0.08
|
0.20
0.18 – 0.22
+185.7% YoY
|
0.33
0.30 – 0.36
+65.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher Seto | Chief Executive Officer, Interim Chief Financial Officer & Director | 483.0K | male |
| John A. Kellum | Chief Medical Officer | 478.8K | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EDT.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
